Your browser doesn't support javascript.
loading
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
Khairnar, Rahul; Pugh, Stephanie L; Sandler, Howard M; Lee, W Robert; Villalonga Olives, Ester; Mullins, C Daniel; Palumbo, Francis B; Bruner, Deborah W; Shaya, Fadia T; Bentzen, Soren M; Shah, Amit B; Malone, Shawn C; Michalski, Jeff M; Dayes, Ian S; Seaward, Samantha A; Albert, Michele; Currey, Adam D; Pisansky, Thomas M; Chen, Yuhchyau; Horwitz, Eric M; DeNittis, Albert S; Feng, Felix Y; Mishra, Mark V.
Afiliación
  • Khairnar R; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Pugh SL; NRG Oncology Statistics and Data Management Center, Philadelphia, PA, United States of America.
  • Sandler HM; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
  • Lee WR; Department of Radiation Oncology, Duke University, Durham, NC, United States of America.
  • Villalonga Olives E; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Mullins CD; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Palumbo FB; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Bruner DW; Department of Radiation Oncology, Emory University, Atlanta, GA, United States of America.
  • Shaya FT; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Bentzen SM; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.
  • Shah AB; WellSpan Health-York Cancer Center, York, PA, United States of America.
  • Malone SC; Ottawa Hospital and Cancer Center, Ottawa, ON, Canada.
  • Michalski JM; Department of Radiation Oncology, Washington University, St. Louis, MO, United States of America.
  • Dayes IS; Juravinski Cancer Center at Hamilton Health Sciences, Hamilton, ON, Canada.
  • Seaward SA; Kaiser Permanente Northern California, Oakland, CA, United States of America.
  • Albert M; Saint Anne's Hospital, Fall River, MA, United States of America.
  • Currey AD; Zablocki VAMC and the Medical College of Wisconsin, Milwaukee, WI, United States of America.
  • Pisansky TM; Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN, United States of America.
  • Chen Y; Department of Radiation Oncology, University of Rochester, Rochester, NY, United States of America.
  • Horwitz EM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States of America.
  • DeNittis AS; Department of Radiation Oncology, Main Line Health, Philadelphia, PA, United States of America.
  • Feng FY; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States of America.
  • Mishra MV; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States of America.
PLoS One ; 16(4): e0249123, 2021.
Article en En | MEDLINE | ID: mdl-33852571
ABSTRACT

PURPOSE:

The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities. METHODS AND MATERIALS This is a secondary analysis of a prospective, randomized non-inferiority clinical trial, conducted between 04/2006 and 12/2009 at cancer centers across the United States, Canada, and Switzerland. Eligible patients included men >18 years with a known diagnosis of low-risk PC. Patient HRQoL data were collected using EPIC and health utilities were obtained using EQ5D. Data were divided into an estimation sample (n = 765, 70%) and a validation sample (n = 327, 30%). The mapping algorithms that capture the relationship between the instruments were estimated using ordinary least squares (OLS), Tobit, and two-part models. Five-fold cross-validation (in-sample) was used to compare the predictive performance of the estimated models. Final models were selected based on root mean square error (RMSE).

RESULTS:

A total of 565 patients in the estimation sample had complete information on both EPIC and EQ5D questionnaires at baseline. Mean observed EQ5D utility was 0.90±0.13 (range 0.28-1) with 55% of patients in full health. OLS models outperformed their counterpart Tobit and two-part models for all pre-determined model specifications. The best model fit was "EQ5D utility = 0.248541 + 0.000748*(Urinary Function) + 0.001134*(Urinary Bother) + 0.000968*(Hormonal Function) + 0.004404*(Hormonal Bother)- 0.376487*(Zubrod) + 0.003562*(Urinary Function*Zubrod)"; RMSE was 0.10462.

CONCLUSIONS:

This is the first study to identify a comprehensive set of mapping algorithms to generate EQ5D utilities from EPIC domain/ sub-domain scores. The study results will help estimate quality-adjusted life-years in PC economic evaluations.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Costo de Enfermedad / Años de Vida Ajustados por Calidad de Vida Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Costo de Enfermedad / Años de Vida Ajustados por Calidad de Vida Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
...